This compound was the main compound of my master thesis and I have included a part of the introduction:

Griseofulvin was first isolated from Penicillium Griseo-Fulvum in 1939 by A. E. Oxford, H. Raistrick and P. Simonart. The compound was reported a "curling factor" in 1946 and inhibits fungal mitosis by disruption of the mitotic spindle. The relative stereochemistry of griseofulvin was established in 1952 and the absolute in 1959. A crystal structure has since verified this stereochemistry. A very comprehensive study of the structure activity relationship for the antifungal activity of griseofulvin has been reported since it’s discovery. Papers were published in the fifties, the sixties but also later in 1971 and in the nineties. The
latest paper was published in 2006 with a 3D-QSAR study of griseofulvin. Several analogs were found to be more active than griseofulvin. The most potent was substituted at ring C at the 2’ and 3’ positions.
In 1996 a composition including griseofulvin was patented for inhibiting the growth of cancer. It has since been reported in 2001 and 2005 that griseofulvin induces apoptosis and cell cycle arrest in human cancer cells. In 2006 analogs of griseofulvin were tested for anticancer activity and it was reported that 2’-demethoxy-2’-propoxygriseofulvin was more active than griseofulvin itself. Recently more analogs of griseofulvin have been tested for anticancer activity and a number of 2’ enol ether analogs were more active than griseofulvin.